FTC’s over-focus on prices misses out on innovation, says pharma lawyer
The problem with antitrust in the pharmaceutical sector is that the Federal Trade Commission has an “obsessive focus” on price, Munger Tolles & Olson partner Rohit Singla has said.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10